Polarean Imaging plc
07/18/2024 | Press release | Archived content
PDMR Dealing
Corporate News
PDMR Dealing
18 July 2024
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces it has received notification today from Bill Blair, an Independent Non-Executive Director ("NED") who is considered by the Company to be a person discharging managerial responsibility ("PDMR"), that he sold 650,000 ordinary shares of £0.00037 each in the capital of the Company ("Ordinary Shares") on 17 July 2024 and 2,039 Ordinary Shares on 18 July 2024, all at a price of 1.8p per Ordinary Share.
Notifications have been made in accordance with the requirements of the UK Market Abuse Regulation in respect of the PDMR and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information
Enquiries:
| Polarean Imaging plc | https://www.polarean.com / https://www.polarean-ir.com | |||||
| Christopher von Jako, Ph.D, Chief Executive Officer | Via Walbrook PR | |||||
| Charles Osborne, Chief Financial Officer | ||||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | |||||
| Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) | ||||||
| Nick Harland (Corporate Broking) | ||||||
| Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
|||||
| Anna Dunphy / Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082 | |||||
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit https://www.polarean.com.
« back to Corporate News
Latest News
-
Holding(s) in Company
11 September 2025 -
Submission of new Phase III study protocol to FDA for expanded indication of XENOVIEW
12 August 2025 -
Block Listing Six Monthly Return
24 July 2025
Corporate News
View About us
About Us
Share Price
Share Price
-
GBp
-
-
-
Annual Report & Account 2024 (inc. Notice of AGM)
Latest Annual Report
Important Dates
Important dates
09 Jun
Annual General Meeting
08 May
Final Results
Investor Alert
Sign up for Email Alerts
Investor Alert
Polarean Imaging plc published this content on July 18, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 15, 2025 at 10:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]